Showing results (141-150 of 193) with videos related to
Sort By:
Pageof 20
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 15, 2015
Cerebral microcirculatory failure after subarachnoid hemorrhage is reversed by hyaluronidaseEvan D McConnell, Helen S Wei, Katherine M Reitz, et al.The Journal of Clinical Investigation|August 1, 1993
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expressionA E Thigpen, R I Silver, J M Guileyardo, et al.The Journal of Urology|August 1, 1994
Expression and regulation of steroid 5 alpha-reductase 2 in prostate diseaseR I Silver, E L Wiley, D L Davis, et al.The Journal of Urology|August 1, 1993
Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasiaM J Barry, A T Cockett, H L Holtgrewe, et al.The Journal of Biological Chemistry|January 29, 2002
The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2Zhi Wang, Ching-Ping Tseng, Rey-Chen Pong, et al.The Journal of Urology|August 1, 1994
Cell type specific expression of steroid 5 alpha-reductase 2R I Silver, E L Wiley, A E Thigpen, et al.International Journal of Public Health|July 2, 2016
Setting-based interventions to promote mental health at the university: a systematic reviewA Fernandez, E Howse, M Rubio-Valera, et al.Child: Care, Health and Development|January 9, 2013
Functioning and post-school transition outcomes for young people with Down syndromeK-R Foley, P Jacoby, S Girdler, et al.The Journal of Urology|September 1, 1995
The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study GroupB M Berger, A Naadimuthu, A Boddy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasisShahrokh F Shariat, Claus G Roehrborn, John D McConnell, et al.Pageof 20